Nanobiotix Advances Curadigm Nanoprimer Platform with New Patents and Preclinical Data

Nanobiotix ( (NBTX) ) has issued an announcement.

On November 13, 2025, Nanobiotix announced significant advancements in its Curadigm Nanoprimer platform, including the filing of four new patent applications to expand its intellectual property portfolio. The company presented new preclinical data at the 2025 Partnership Opportunities in Drug Delivery conference, showcasing the Nanoprimer’s potential to improve the delivery of therapeutic vaccines. These developments are expected to drive long-term growth for Nanobiotix by supporting both internal pipeline development and external collaborations, with numerous material transfer agreements already in place.

The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.

Spark’s Take on NBTX Stock

According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.

Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.

To see Spark’s full report on NBTX stock, click here.

More about Nanobiotix

Nanobiotix is a late-stage clinical biotechnology company focused on developing physics-based therapeutic approaches to improve treatment outcomes for cancer and other major diseases. The company, headquartered in Paris, France, is listed on Euronext Paris and the Nasdaq Global Select Market. It owns over 25 patents related to oncology, bioavailability, biodistribution, and central nervous system disorders.

Average Trading Volume: 90,553

Technical Sentiment Signal: Buy

Current Market Cap: $1.03B

See more insights into NBTX stock on TipRanks’ Stock Analysis page.